Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges
Authors
Keywords
-
Journal
Frontiers in Genetics
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-27
DOI
10.3389/fgene.2020.00480
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile
- (2020) Katherine Tarlock et al. BLOOD
- Recent advances in the development of Mcl-1 inhibitors for cancer therapy
- (2019) Alexander W. Hird et al. PHARMACOLOGY & THERAPEUTICS
- New drugs creating new challenges in acute myeloid leukemia
- (2019) Ing S. Tiong et al. GENES CHROMOSOMES & CANCER
- Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) Martin S. Tallman et al. Journal of the National Comprehensive Cancer Network
- Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
- (2019) Juan Huang et al. Frontiers in Oncology
- Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma
- (2019) Makoto Nakagawa et al. ONCOGENE
- Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
- (2019) Maeve A Lowery et al. Lancet Gastroenterology & Hepatology
- A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results
- (2019) Amer M. Zeidan et al. BLOOD
- HDAC Inhibitors in Acute Myeloid Leukemia
- (2019) San José-Enériz et al. Cancers
- The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
- (2018) Eytan M. Stein et al. BLOOD
- Current status and trends in the diagnostics of AML and MDS
- (2018) Evgenii Shumilov et al. BLOOD REVIEWS
- Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
- (2018) Weiguo Zhang et al. HAEMATOLOGICA
- Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA
- (2018) Feng-Ming Tien et al. HAEMATOLOGICA
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
- (2018) Amy Y. Wang et al. Journal of Hematology & Oncology
- A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
- (2018) Shyamala C. Navada et al. LEUKEMIA RESEARCH
- Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
- (2018) Weiguo Zhang et al. HAEMATOLOGICA
- Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA
- (2018) Feng-Ming Tien et al. HAEMATOLOGICA
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial
- (2018) Juliette Lambert et al. HAEMATOLOGICA
- Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.
- (2018) Bhavana Bhatnagar et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
- (2018) Andrew M. Intlekofer et al. NATURE
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
- (2018) Naval Daver et al. Cancer Discovery
- Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse
- (2017) Brian Parkin et al. JOURNAL OF CLINICAL INVESTIGATION
- Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
- (2017) Nicolas Floc'h et al. MOLECULAR CANCER THERAPEUTICS
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH -Mutant Molecular Profiles
- (2017) Farshad Farshidfar et al. Cell Reports
- The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR
- (2016) L. Zhou et al. BLOOD
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials
- (2016) Armin Rashidi et al. BLOOD
- A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
- (2016) Steven Knapper et al. BLOOD
- TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
- (2016) Penka S. Petrova et al. CLINICAL CANCER RESEARCH
- Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
- (2016) Amir T. Fathi et al. HAEMATOLOGICA
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Genomic Classification in Acute Myeloid Leukemia
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gli-1/PI3K/AKT/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells
- (2016) Xiaodong Li et al. Oncotarget
- The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
- (2016) Sung Hee Lim et al. Oncotarget
- Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
- (2016) Amir T. Fathi et al. HAEMATOLOGICA
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse
- (2015) M. Garg et al. BLOOD
- A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
- (2015) Alan K. Burnett et al. BLOOD
- Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia
- (2015) Yukio Kobayashi et al. CANCER SCIENCE
- Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
- (2015) J. Wellbrock et al. CLINICAL CANCER RESEARCH
- Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
- (2015) M. Andreeff et al. CLINICAL CANCER RESEARCH
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
- (2015) Jie Liu et al. PLoS One
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
- (2014) H. Dohner et al. BLOOD
- p53: The barrier to cancer stem cell formation
- (2014) Ronit Aloni-Grinstein et al. FEBS LETTERS
- The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation
- (2014) Hiba Ahmad Zahreddine et al. NATURE
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Clinical translation of nuclear export inhibitors in cancer
- (2014) William T. Senapedis et al. SEMINARS IN CANCER BIOLOGY
- Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
- (2013) Xiaochuan Yang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia
- (2013) Hagop M. Kantarjian et al. CANCER
- A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
- (2013) James Foran et al. Clinical Lymphoma Myeloma & Leukemia
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
- (2013) D. Tseng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
- (2012) A. Sexauer et al. BLOOD
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3
- (2012) Marshall A. Lichtman BLOOD CELLS MOLECULES AND DISEASES
- Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
- (2012) Mike Dennis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia
- (2012) Alison R. Walker et al. LEUKEMIA & LYMPHOMA
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
- (2011) T. Sato et al. BLOOD
- Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
- (2011) B. Lowenberg et al. BLOOD
- DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis
- (2011) A. T. Nguyen et al. BLOOD
- FLT3/ITD AML and the law of unintended consequences
- (2011) M. Levis BLOOD
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
- (2011) F. G. Rucker et al. BLOOD
- Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
- (2011) Jorge Cortes et al. CANCER
- Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
- (2011) Scott R. Daigle et al. CANCER CELL
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
- (2011) Kathrin M. Bernt et al. CANCER CELL
- Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia
- (2011) S. H. Kaufmann et al. HAEMATOLOGICA
- IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
- (2011) M Fernanda Amary et al. JOURNAL OF PATHOLOGY
- A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
- (2011) Kosuke Tsuboi et al. LEUKEMIA RESEARCH
- Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells
- (2011) D. Li et al. MOLECULAR CANCER RESEARCH
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Overexpression of Active Aurora-C Kinase Results in Cell Transformation and Tumour Formation
- (2011) Jabbar Khan et al. PLoS One
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia
- (2009) I. H. I. M. Hollink et al. BLOOD
- Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
- (2009) A. G. Renner et al. BLOOD
- PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
- (2009) Jeremy M.R. Lambert et al. CANCER CELL
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
- (2008) Richard K. Tsai et al. JOURNAL OF CELL BIOLOGY
- Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
- (2008) Arthur Frankel et al. LEUKEMIA & LYMPHOMA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now